Skip to main content
Find more clinical trials

Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU)

Start: December 2012
End: October 2027
Enrollment: 490

What Is This Study About?

This ongoing study is testing the safety and effectiveness of several experimental drugs to slow the progression of cognitive impairment in people with an inherited Alzheimer's disease-causing gene mutation. Specifically, mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP) genes are associated with inherited Alzheimer's disease. All participants will be tested to determine if they have one of the mutations. Participants found to have one of the mutations will be randomly assigned to receive injections of one of the study drugs. Those participants who do not have a mutation will be randomly assigned to receive injections of either a study drug or a placebo. Injections will be given every four weeks for up to 208 weeks. Researchers will measure changes in cognition, blood and spinal fluid biomarkers, abnormal amyloid and tau protein in the brain, and brain glucose metabolism. Measurements will be done at the start of the study and then again at weeks 52, 104, 156, and 208. The study, called DIAN-TU, will test several different study drugs, starting with gantenerumab and solanezumab.

Do I Qualify To Participate in This Study?

Minimum Age: 18 Years

Maximum Age: 80 Years

Must have:

  • Have a genetic mutation that causes Alzheimer's disease or are a family member with an dominantly inherited Alzheimer's disease (DIAD) mutation
  • No more than 10 years after the predicted or actual age of cognitive symptom onset
  • Cognitively normal or with mild cognitive impairment or mild dementia (Clinical Dementia Rating score of 0 to 1)
  • Fluency in trial-approved language and adequate intellectual functioning (aside from mild impairment)
  • Able to undergo magnetic resonance imaging (MRI), lumbar puncture, and positron emission tomography and to complete all study-related testing and evaluations
  • Females of childbearing potential must agree to use effective contraception if partner is not sterile
  • Visual and hearing abilities adequate to complete cognitive and functional assessments
  • Study partner who can attend visits and provide information on participant's cognitive and functional abilities

Must NOT have:

  • Evidence of significant abnormality on brain MRI scans
  • Alcohol or drug dependence within past year
  • Pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin, or body that would prevent MRI
  • History or presence of significant cardiovascular disease, liver/kidney disorders, infectious disease or immune disorder, or metabolic/endocrine disorders
  • Taking anticoagulants; low-dose aspirin (325 mg or less) is allowed
  • Exposed to a monoclonal antibody-targeting beta-amyloid peptide within past 6 months
  • Cancer in last 5 years, except basal cell carcinoma, nonsquamous skin carcinoma, prostate cancer, or carcinoma in situ with no significant progression in past 2 years
  • Positive pregnancy test or plans to become pregnant during the trial period

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.


Who Is the General Study Contact?

For more information about this study or study sites, visit the study website, call 1-844-342-6397, or email

Study Contact
Ellen Ziegemeier, MA

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

University of Alabama in Birmingham
Birmingham, AL 35294
University of California San Diego Medical Center
La Jolla, CA 92037
USC Keck School of Medicine
Los Angeles, CA 90033
Not yet recruiting
Emory University
Atlanta, GA 30329
Advocate Lutheran General Hospital
Park Ridge, IL 60068
Indiana University School of Medicine
Indianapolis, IN 46202
Washington University in St. Louis
Saint Louis, MO 63110
University of Pittsburgh
Pittsburgh, PA 15213
Rhode Island
Butler Hospital
Providence, RI 02096
Kerwin Medical Center
Dallas, TX 75231
Not yet recruiting
University of Washington
Seattle, WA 98195

Who Sponsors This Study?

Lead: Washington University School of Medicine

Collaborator Sponsor

  • Eli Lilly and Company
  • Hoffmann-La Roche
  • Alzheimer's Association
  • National Institute on Aging (NIA)
  • Avid Radiopharmaceuticals
  • Accelerating Medicines Partnership (AMP)
  • Janssen, LP

Source: ID: NCT01760005